Your browser doesn't support javascript.
loading
A miR-137-Related Biological Pathway of Risk for Schizophrenia Is Associated With Human Brain Emotion Processing.
Pergola, Giulio; Rampino, Antonio; Sportelli, Leonardo; Borcuk, Christopher James; Passiatore, Roberta; Di Carlo, Pasquale; Marakhovskaia, Aleksandra; Fazio, Leonardo; Amoroso, Nicola; Castro, Mariana Nair; Domenici, Enrico; Gennarelli, Massimo; Khlghatyan, Jivan; Kikidis, Gianluca Christos; Lella, Annalisa; Magri, Chiara; Monaco, Alfonso; Papalino, Marco; Parihar, Madhur; Popolizio, Teresa; Quarto, Tiziana; Romano, Raffaella; Torretta, Silvia; Valsecchi, Paolo; Zunuer, Hailiqiguli; Blasi, Giuseppe; Dukart, Juergen; Beaulieu, Jean Martin; Bertolino, Alessandro.
Afiliação
  • Pergola G; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland; Department of Psychiatry and Behavioral Sciences, Johns Hopkins Universit
  • Rampino A; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy. Electronic address: antonio.rampino@uniba.it.
  • Sportelli L; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland.
  • Borcuk CJ; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland.
  • Passiatore R; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Institute of Neuroscience and Medicine, Brain & Behaviour, Research Centre Jülich, Jülich, Germany.
  • Di Carlo P; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.
  • Marakhovskaia A; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
  • Fazio L; Department of Medicine and Surgery, Libera Università Mediterranea Giuseppe Degennaro, Casamassima, Italy.
  • Amoroso N; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Bari, Italy; Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Bari, Italy.
  • Castro MN; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Consejo Nacional de Investigaciones Científicas y Técnicas, Ciudad Autónoma de Buenos Aires, Argentina (MNC); Grupo de Investigación en Neurociencias Aplicadas a la
  • Domenici E; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy; Fondazione The Microsoft Research University of Trento, Centre for Computational and Systems Biology, Rovereto, Italy.
  • Gennarelli M; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, Istituto di Ricovero e Cura a Carattere Sanitario Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Khlghatyan J; Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Kikidis GC; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland.
  • Lella A; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.
  • Magri C; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Monaco A; Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Bari, Italy; Consejo Nacional de Investigaciones Científicas y Técnicas, Ciudad Autónoma de Buenos Aires, Argentina (MNC); Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta, Fleni-Consejo Nacional de Investigac
  • Papalino M; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.
  • Parihar M; Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland.
  • Popolizio T; Istituto di Ricovero e Cura a Carattere Sanitario Istituto Centro San Giovanni di Dio Fatebenefratelli, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Quarto T; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Department of Law, University of Foggia, Foggia, Italy.
  • Romano R; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.
  • Torretta S; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.
  • Valsecchi P; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of Mental Health and Addiction Services, Azienda Socio Sanitaria Territoriale Spedali Civili of Brescia, Brescia, Italy.
  • Zunuer H; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy.
  • Blasi G; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.
  • Dukart J; Institute of Neuroscience and Medicine, Brain & Behaviour, Research Centre Jülich, Jülich, Germany; Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Beaulieu JM; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
  • Bertolino A; Group of Psychiatric Neuroscience, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy; Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.
Article em En | MEDLINE | ID: mdl-38000716
BACKGROUND: miR-137 is a microRNA involved in brain development, regulating neurogenesis and neuronal maturation. Genome-wide association studies have implicated miR-137 in schizophrenia risk but do not explain its involvement in brain function and underlying biology. Polygenic risk for schizophrenia mediated by miR-137 targets is associated with working memory, although other evidence points to emotion processing. We characterized the functional brain correlates of miR-137 target genes associated with schizophrenia while disentangling previously reported associations of miR-137 targets with working memory and emotion processing. METHODS: Using RNA sequencing data from postmortem prefrontal cortex (N = 522), we identified a coexpression gene set enriched for miR-137 targets and schizophrenia risk genes. We validated the relationship of this set to miR-137 in vitro by manipulating miR-137 expression in neuroblastoma cells. We translated this gene set into polygenic scores of coexpression prediction and associated them with functional magnetic resonance imaging activation in healthy volunteers (n1 = 214; n2 = 136; n3 = 2075; n4 = 1800) and with short-term treatment response in patients with schizophrenia (N = 427). RESULTS: In 4652 human participants, we found that 1) schizophrenia risk genes were coexpressed in a biologically validated set enriched for miR-137 targets; 2) increased expression of miR-137 target risk genes was mediated by low prefrontal miR-137 expression; 3) alleles that predict greater gene set coexpression were associated with greater prefrontal activation during emotion processing in 3 independent healthy cohorts (n1, n2, n3) in interaction with age (n4); and 4) these alleles predicted less improvement in negative symptoms following antipsychotic treatment in patients with schizophrenia. CONCLUSIONS: The functional translation of miR-137 target gene expression linked with schizophrenia involves the neural substrates of emotion processing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / MicroRNAs Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / MicroRNAs Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article